東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

The new drug reimbursement game = a ...

Pekarsky, Brita A.K.

Linked to FindBook

Google Book

Amazon

博客來

The new drug reimbursement game = a regulator's guide to playing and winning /

Record Type:	Electronic resources : Monograph/item
Title/Author:	The new drug reimbursement game/ by Brita A.K. Pekarsky.
Reminder of title:	a regulator's guide to playing and winning /
Author:	Pekarsky, Brita A.K.
Published:	Cham :Springer International Publishing : : 2015.,
Description:	xvi, 248 p. :ill., digital ;24 cm.
[NT 15003449]:	Introduction -- Reframing the political economy of new drugs -- The social rate of return on investment in pharmaceutical R&D -- The value of innovation -- The shadow price -- The health shadow price -- The health shadow price and the economic context -- The `pharmaceutical R&D financing' game -- The `pharmacotherapy needs a premium' game -- Conclusion.
Contained By:	Springer eBooks
Subject:	Medical care - Marketing. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-08903-4
ISBN:	9783319089034 (electronic bk.)

The new drug reimbursement game = a regulator's guide to playing and winning /
Pekarsky, Brita A.K.

The new drug reimbursement gamea regulator's guide to playing and winning /[electronic resource] :by Brita A.K. Pekarsky. - Cham :Springer International Publishing :2015. - xvi, 248 p. :ill., digital ;24 cm.

Introduction -- Reframing the political economy of new drugs -- The social rate of return on investment in pharmaceutical R&D -- The value of innovation -- The shadow price -- The health shadow price -- The health shadow price and the economic context -- The `pharmaceutical R&D financing' game -- The `pharmacotherapy needs a premium' game -- Conclusion.

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population's future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society's welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm's production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price. The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.

ISBN: 9783319089034 (electronic bk.)

Standard No.: 10.1007/978-3-319-08903-4doiSubjects--Topical Terms:

814441
Medical care
--Marketing.

LC Class. No.: RA410.56

Dewey Class. No.: 362.1068

The new drug reimbursement game = a regulator's guide to playing and winning /
LDR:03461nmm a2200313 a 4500 001 1993240
003 DE-He213
005 20150622165544.0
006 m d
007 cr nn 008maaau
008 151019s2015 gw s 0 eng d
020 $a 9783319089034 (electronic bk.)
020 $a 9783319089027 (paper)
024 7 $a 10.1007/978-3-319-08903-4 $2 doi
035 $a 978-3-319-08903-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RA410.56
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 362.1068 $2 23
090 $a RA410.56 $b .P379 2015
100 1 $a Pekarsky, Brita A.K. $3 2131345
245 1 4 $a The new drug reimbursement game $h [electronic resource] : $b a regulator's guide to playing and winning / $c by Brita A.K. Pekarsky.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a xvi, 248 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Reframing the political economy of new drugs -- The social rate of return on investment in pharmaceutical R&D -- The value of innovation -- The shadow price -- The health shadow price -- The health shadow price and the economic context -- The `pharmaceutical R&D financing' game -- The `pharmacotherapy needs a premium' game -- Conclusion.
520 $a This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population's future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society's welfare. The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm's production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price. The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated. Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system. Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price. PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.
650 0 $a Medical care $x Marketing. $3 814441
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Pharmacoeconomics and Health Outcomes. $3 2089175
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
650 2 4 $a Medicine/Public Health, general. $3 891342
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-08903-4
950 $a Medicine (Springer-11650)